GridAI Technologies Corp.
Support and Resistance Levels
Past performance
News About GRDX
All events for GRDX
All deals for GRDX
Financial Ratios
Financial Statements
GRDX vs Sector & Peers
About GridAI Technologies Corp.
GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida. Website grid-ai.com
Headquarters Edinburgh, FL, GB